^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD79A mutation

    i
    Other names: CD79A, CD79a Molecule, B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain, MB-1, IGA, Membrane-Bound Immunoglobulin-Associated Protein, CD79a Molecule, Immunoglobulin-Associated Alpha, Surface IgM-Associated Protein, MB-1 Membrane Glycoprotein, Ig-Alpha, CD79A Antigen (Immunoglobulin-Associated Alpha), CD79a Antigen (Immunoglobulin-Associated Alpha), CD79a Antigen, MB1
    Entrez ID:
    973
    Related biomarkers:
    Mutation
    Apply
    Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626)
    Phase 2
    Chinese Academy of Medical Sciences
    Not yet recruiting
    Last update posted :
    08/06/2021
    Initiation :
    10/01/2021
    Primary completion :
    04/01/2022
    Completion :
    07/01/2025
    CD20 • MYD88 • CD79B • CD79A
    |
    CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab)